FDA Approves CARBIDOPA AND LEVODOPA — Aurobindo Pharma Limited

Aurobindo Pharma Limited secured FDA approval for its generic Carbidopa and Levodopa oral tablet, positioning the company to capitalize on cost-sensitive demand in the Parkinson’s disease market. This clearance is anticipated to generate incremental revenue by offering a more affordable alternative to branded formulations, intensifying competitive pressure in the space.